MTST (MetaStat) Preferred Dividends: $0.10 Mil (TTM As of Feb. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MetaStat Preferred Dividends?

MetaStat MTST Preferred Dividends is $0.10 Mil as of Feb. 2018.

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. MetaStat's preferred dividends for the three months ended in Feb. 2018 was $0.03 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Feb. 2018 was $0.10 Mil.

MetaStat  (OTCPK:MTST) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Feb. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Preferred Dividends Historical Data

* Premium members only.

The historical data trend for MetaStat's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MetaStat Preferred Dividends Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Preferred Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.24 1.34 3.28 0.10

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.37 0.02 0.03 0.03 0.03

MetaStat Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Frequently Asked Questions Learn more about Preferred Dividends →
What does a Preferred Dividends of $0.10 Mil mean?
MetaStat (MTST) has a Preferred Dividends of $0.10 Mil as of Feb. 2018. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on MetaStat and its competitors.
Is MetaStat's Preferred Dividends too high?
MetaStat's current Preferred Dividends is $0.10 Mil.
How does MetaStat's Preferred Dividends compare to OBMP and NSPX?
MetaStat's Preferred Dividends of $0.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Dividends for a Biotechnology company?
A good Preferred Dividends depends on the Biotechnology industry context. However, Preferred Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Dividends mean?
A high Preferred Dividends can signal that a stock is expensive relative to its fundamentals. Preferred Dividends is the total amount a company pays out as dividends on its preferred shares. View historical data on MetaStat and its competitors. MetaStat's current Preferred Dividends is $0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current Preferred Dividends of $0.10 Mil. The current Preferred Dividends is $0.10 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Dividends calculated?
Preferred Dividends is calculated from a company's financial statements. For MetaStat (MTST), the current Preferred Dividends is $0.10 Mil as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.